WWGKKYRASKLGLAR|CAS 130154-64-2|DC Chemicals

Cas No.:	130154-64-2
Chemical Name:	WWGKKYRASKLGLAR
Formula:	C₈₆H₁₃₄N₂₆O₁₈
M.Wt:	1820.1
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC72349	CP-447697	CP-447697 is a lipophilic C5a receptor antagonist with an IC50 value of 31 nM. CP-447697 can be used for the research of inflammation.
DC44151	Complement factor D-IN-2	Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases.
DC28985	(Z)-Leukadherin-1	(Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.
DC11082	Danicopan (ACH-4471)	Danicopan (ACH-4471, ACH-0144471) is a highly potent, orally active Factor D inhibitor with Kd of 0.54 nM, inhibits the proteolytic activity of purified Factor D against substrate Factor B in complex with C3b, blocking production of Bb fragment IC50 of 15 nM.
DC11688	Avacopan	Avacopan is a potent, selective, orally availale C5aR (CD88) inhibitor with IC50 of 0.1 nM.
DC76678	Tarvicopan	Tarvicopan is an inhibitor for complement factor D.
DC73517	WWGKKYRASKLGLAR	Peptide WWGKKYRASKLGLAR is a super agonist of complement factor C3aR, 12-15 times more active than natural C3a.
DC73516	T-ALZ01	T-ALZ01 (CMP-1696) is a small molecule inhibitor of complement component C1r.
DC73515	DF3016A	DF3016A (DF 3016A) is a potent and selective C5aR inhibitor with IC50 of 50 nM (C5a-induced human PMN migration and IC50 of 45 and 37 nM against rat and mouse C5aR, respectively.
DC73514	CMP-1611	CMP-1611 is a small molecule inhibitor of protease of the complement classical pathway, C1r, directly inhibits classical pathway-specific complement activation in a dose-dependent manner.